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ABSTRACT 23 
The fungal Cyp51-specific inhibitors VT-1161 and VT-1598 have emerged as promising new 24 
therapies to combat fungal infections, including Candida spp.  To evaluate their in vitro activities 25 
compared to other azoles, minimum inhibitory concentrations (MICs) were determined by CLSI 26 
method for VT-1161, VT-1598, fluconazole, voriconazole, itraconazole, and posaconazole 27 
against 68 C. albicans clinical isolates well-characterized for azole resistance mechanisms and 28 
mutant strains representing individual azole resistance mechanisms.  VT-1161 and VT-1598 29 
demonstrated potent activity (geometric mean MICs ≤0.15 μg/mL) against predominantly 30 
fluconazole-resistant (≥8 µg/mL) isolates.  However, five of 68 isolates exhibited MICs greater 31 
than six dilutions (>2 μg/mL) to both tetrazoles compared to fluconazole-susceptible isolates.  32 
Four of these isolates likewise exhibited high MICs beyond the upper limit of the assay for all 33 
triazoles tested.  A premature stop codon in ERG3 likely explained the high-level resistance in 34 
one isolate. VT-1598 was effective against strains with hyperactive Tac1, Mrr1, and Upc2 35 
transcription factors and against most ERG11 mutant strains. VT-1161 MICs were elevated 36 
compared to the control strain SC5314 for hyperactive Tac1 strains and two strains with Erg11 37 
substitutions (Y132F and Y132F&K143R), but showed activity against hyperactive Mrr1 and 38 
Upc2 strains.  While mutations affecting Erg3 activity appear to greatly reduce susceptibility to 39 
VT-1161 and VT-1598, the elevated MICs of both tetrazoles for four isolates could not be 40 
explained by known azole resistance mechanisms, suggesting the presence of undescribed 41 
resistance mechanisms to triazole- and tetrazole-based sterol demethylase inhibitors. 42 
 43 
 44 
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INTRODUCTION 45 
Candida albicans is a dimorphic yeast and opportunistic pathogen that is known to cause 46 
a wide range of infections in healthy and immunocompromised patients.  In the United States, 47 
C. albicans is the leading Candida species identified in oropharyngeal and vulvovaginal 48 
infections, where recurrent infections remain problematic (1-5).  In more serious systemic 49 
disease such as bloodstream infections (BSI), Candida species collectively are the fourth-50 
leading cause of nosocomial BSI in the United States (6). Moreover, resistance to currently 51 
available antifungal agents continues to be a problem, particularly given the relatively limited 52 
armamentarium against fungal infections (7-11).  In particular, azole antifungal resistance in 53 
Candida spp. threatens to diminish the efficacy of arguably the most widely used antifungal 54 
drug class (12).  Appropriate clinical use of available drugs on the market and eventual 55 
expansion of the antifungal arsenal is therefore paramount to safeguarding its effectiveness. 56 
 Azole antifungal resistance in C. albicans can be attributed to multiple mechanisms.  57 
First, efflux pump overexpression, such as the ATP-binding cassette (ABC) transporters Cdr1 58 
and Cdr2 as well as the major facilitator transporter Mdr1, prevents drug accumulation within 59 
the yeast cell (13-16).  Second, increased production of the azole target 14α-lanosterol 60 
demethylase (CYP51) can attenuate the inhibitory effects of the azoles drug class (17-19). 61 
Increases in efflux pump and drug target production is often the result of gain-of-function 62 
mutations in zinc cluster transcription factors (ZCFs) (Tac1 for CDR1 and CDR2, Mrr1 for 63 
MDR1, Upc2 for ERG11) that regulate their gene expression, though polyploidy of 64 
chromosomes in the yeast genome can also result in increased expression of the genes encoding 65 
these azole-resistance determinants. Third, mutations in ERG11 can confer azole resistance 66 
through alteration of the drug target (20-23).  Lastly, alternative sterol biosynthesis as a result 67 
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of changes within the ergosterol biosynthetic pathway allows some C. albicans isolates to 68 
circumvent the effects of azole inhibition altogether (24-27). 69 
VT-1161 and VT-1598 are novel tetrazole antifungal agents with high specificity for 70 
fungal CYP51 compared to human CYP enzymes (28-30), and thus may have improved adverse 71 
effect and drug-drug interaction profiles due to lesser off-target inhibition.  In this study, we 72 
compare the in vitro activity of the novel tetrazoles VT-1161 and VT-1598 to the current 73 
triazole antifungals fluconazole, voriconazole, itraconazole, and posaconazole against a 74 
collection of clinical isolates and laboratory strains with known resistance mechanisms. 75 
 76 
RESULTS 77 
In vitro activity of VT-1161 and VT-1598 against fluconazole-susceptible and fluconazole-78 
resistant clinical isolates.  VT-1161 and VT-1598 showed potent in vitro activity against 68 79 
previously described clinical isolates of C. albicans, the majority (57 of 68) of which were 80 
fluconazole-resistant (MIC ≥8 μg/mL) and possessed multiple known azole resistance 81 
mechanisms (Table S1) (19).  Both VT-1161 and VT-1598 had lower MIC50 values (0.06 and 82 
0.125 µg/mL, respectively), and VT-1598 had a lower MIC90 value (0.25 µg/mL) when 83 
compared to the other tested azole antifungals (Table 1).  VT-1161 and VT-1598 MICs were 84 
≤0.015 µg/mL against the 11 fluconazole-susceptible isolates within the collection, and the VT-85 
1598 MICs were 0.03 µg/mL against 33% (19 of 57) of the fluconazole-resistant clinical isolates.  86 
This suggests that some fluconazole-resistance mechanisms do not affect the in vitro potency of 87 
VT-1598.  Posaconazole also demonstrated activity against many, but not all, of the same 88 
fluconazole-resistant isolates, as posaconazole MICs were within a two-fold increase (1-dilution 89 
difference) to those of the fluconazole-susceptible isolates for 15 of the fluconazole-resistant 90 
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isolates.  Using this same metric, VT-1161 maintained in vitro potency against 8 fluconazole-91 
resistant clinical isolates, which was comparable to that of voriconazole (6 isolates) and greater 92 
than that of itraconazole (2 isolates).  Overall, VT-1598 and VT-1161 thus appear to have 93 
additional activity against several fluconazole-resistant isolates, and in this respect are at least 94 
comparable to commercially available triazoles. 95 
VT-1598 MICs were elevated at least four-fold (≥0.06 µg/mL, range 0.06 to >8 µg/mL) 96 
against 38 fluconazole-resistant isolates compared to its activity against the fluconazole-97 
susceptible isolates.  VT-1161 MICs were elevated at least four-fold (≥0.06 µg/mL, range 0.06 to 98 
>8 µg/mL) against 49 fluconazole-resistant isolates.  Five clinical isolates displayed highly 99 
elevated VT-1598 and VT-1161 MICs (range 4 to >8 μg/mL) and also high fluconazole, 100 
voriconazole, itraconazole, and posaconazole MICs.  Sequencing and/or relative quantitation of 101 
mRNA expression of known resistance genes revealed that four of these isolates overexpressed 102 
CDR1 relative to the CDR1 mRNA levels of fluconazole-susceptible clinical isolates (19). The 103 
fifth isolate contained a premature stop codon in ERG3, resulting in truncation of the protein 104 
after Gly130, which likely explains its significantly elevated resistance not only to VT-1161 and 105 
VT-1598, but also to all other tested azole antifungals. 106 
To gain additional insight on the determinants that could confer decreased susceptibility 107 
to VT-1161 and VT-1598 in the clinical isolates, a point-biserial correlation between the log2-108 
fold increase in VT-1598 and VT-1161 MICs and the mRNA expression levels of CDR1, MDR1, 109 
and ERG11 in the clinical isolates was performed.  The log2-fold increase in MICs was compared 110 
to the baseline MIC measurement for VT-1598 and VT-1161 against fluconazole-susceptible 111 
isolates (MIC ≤ 0.015) and expression levels of either CDR1, MDR1, and ERG11 were measured 112 
via RT-qPCR in a previous study (19).  The majority of fluconazole-resistant clinical isolates 113 
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exhibited increased CDR1 expression, however there was no significant correlation between 114 
CDR1 expression and VT-1598 resistance (p = 0.287). In contrast, higher levels of CDR1 115 
expression did positively correlate with increasing VT-1161 MICs (p < 0.01).  Similarly, while 116 
there was no relationship between MDR1 expression and VT-1598 MIC (p = 0.105), there was a 117 
slight positive correlation between MDR1 expression and increased VT-1161 MIC (p < 0.05).  118 
No significant correlation was established with either drug and ERG11 expression (p = 0.512 and 119 
p = 0.355 for VT-1598 and VT-1161, respectively).   120 
VT-1598 and VT-1161 MICs against the clinical isolates were plotted directly against 121 
those of fluconazole, voriconazole, itraconazole, and posaconazole to visualize relative 122 
susceptibility differences (Figure 1).  As previously noted, both VT-1161 and VT-1598 retained 123 
potency against several fluconazole-resistant isolates, and all isolates with reduced VT-1598 or 124 
VT-1161 potency were resistant to fluconazole.  By comparison, VT-1161 MICs were 125 
disproportionately higher against some clinical isolates compared to those of the other tested 126 
azoles.  One voriconazole-susceptible isolate (0.125 μg/mL) that contained a K143R ERG11 127 
mutation and exhibited increased CDR1 expression had an 8-fold increase in the MIC of VT-128 
1161 compared to that observed against fluconazole-susceptible isolates (≤0.015 µg/mL).   In 129 
addition, a single itraconazole-susceptible isolate (0.125 μg/mL) demonstrated a 32-fold increase 130 
in the VT-1161 MIC (0.5 μg/mL).  This isolate contained three Erg11 amino acid substitutions 131 
(F126L, Y132F, H283R), but lacked other obvious azole resistance mechanisms.  Against 132 
isolates with low posaconazole MICs (range ≤0.03 to 0.25 µg/mL), seven displayed ≥16-fold 133 
increases in VT-1161 MIC over fluconazole-susceptible isolates.  Among these seven isolates, 134 
all contained various ERG11 mutations, four overexpressed CDR1 by at least two-fold, one 135 
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overexpressed both ERG11 and CDR1, and one overexpressed MDR1.  In contrast, there were no 136 
strong outliers for VT-1598 MICs when compared against those of the triazoles. 137 
 138 
In vitro activity of VT-1161 and VT-1598 against strains with known azole 139 
resistance mechanisms.  To identify determinants of VT-1161 and VT-1598 resistance, we 140 
evaluated the influence of specific azole-resistance mechanisms on VT-1161 and VT-1598 MICs 141 
when placed in the fluconazole-susceptible isolate SC5314 (Figure 2).  Increased CDR1 and 142 
CDR2 expression through artificial activation of the TAC1 gene increased the VT-1161 MICs 143 
more than eight-fold compared to the susceptible parent strain.  This increase in VT-1161 MIC 144 
was diminished, but not completely abolished, when the CDR1 gene was deleted, suggesting that 145 
overexpression of CDR1 as well as other Tac1 target genes (most likely CDR2) was responsible 146 
for the decreased susceptibility to VT-1161.  On the other hand, Tac1 activation did not result in 147 
reduced susceptibility to VT-1598, as opposed to its effect on VT-1161, fluconazole and 148 
voriconazole resistance, which increased between four- and 16-fold compared to that of the 149 
parental strain SC5314.  Posaconazole and itraconazole MICs were only slightly elevated (two-150 
fold) by the hyperactive Tac1.  Thus, it appears that while drug efflux via Cdr1 plays a role in 151 
VT-1161 resistance, Tac1 activation and the approximately 10-fold increase in CDR1 expression 152 
are not sufficient to alter MICs of VT-1598. 153 
While a hyperactive Mrr1 did not result in increased resistance to VT-1598, it caused a 154 
four-fold increase in the MIC of VT-1161. This increase was abolished upon MDR1 deletion, 155 
suggesting that the Mdr1 transporter is involved in VT-1161 resistance.  Fluconazole and 156 
voriconazole were the only tested azole drugs against the MDR1-overexpressing strain that 157 
showed a greater than two-fold increase in MIC (32-fold and four-fold, respectively) over 158 
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SC5314.  By comparison, itraconazole showed a minimal two-fold increase (1-dilution 159 
difference) in MIC, and posaconazole MICs were not affected by MDR1 overexpression.  160 
Strangely, there was a 4-fold increase in posaconazole MIC when MDR1 was deleted in the 161 
hyperactive Mrr1 strain.  However, this is consistent with variability observed for posaconazole 162 
MICs in other published strains and fluconazole-susceptible clinical isolates (31). 163 
Upregulated expression of ERG11 via artificial activation of the Upc2 transcription factor 164 
also did not affect VT-1161 or VT-1598 MICs.  However, despite an approximate 4- to 8-fold 165 
increase in ERG11 expression (data not shown), the activated Upc2 strain failed to demonstrate a 166 
relevant change in voriconazole, posaconazole, and itraconazole MICs.  Surprisingly, this strain 167 
also exhibited no change in fluconazole MIC as has previously been reported. We therefore 168 
decided to also test azole susceptibilities in a strain homozygous for the G648D amino acid 169 
substitution, previously shown to be the strongest clinically-derived gain-of-function mutation in 170 
Upc2 (19, 32).  Strains SCUPC2R14A and –B overexpressed ERG11 relative to the parent strain 171 
SC5314 by 6.4-fold (previously published) and 4.5-fold (unpublished data), respectively (data 172 
not shown) (19).  A modest 2-fold increase in fluconazole MIC in these two strains was observed 173 
compared to SC5314, whereas no changes were observed for the MICs of any of the other 174 
antifungal agents. 175 
 To compare the effects of different alterations in the azole target enzyme on the 176 
susceptibility of C. albicans to VT-1161 and VT-1598, twelve single Erg11 amino acid 177 
substitutions and four double substitutions in Erg11 were tested (Table S2, Figure 3).  The 178 
Y132F single substitution caused a substantial (16-fold) increase inVT-1161 MIC.  Surprisingly, 179 
the double amino acid substitutions Y132F&K143R and Y132F&F145L had a lesser impact on 180 
VT-1161 MIC (eight-fold and four-fold increase, respectively) than the single Y132F 181 
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substitution alone.  Other amino acid substitutions did not have an appreciable effect on VT-182 
1161 MICs, and none of the tested ERG11 mutants showed greater than a two-fold increase in 183 
the MIC of VT-1598.  The F145L and S405F single mutants and the double substitution mutants 184 
D278N&G464S and Y132F&F145L showed a slight two-fold increase in the VT-1598 MIC 185 
compared to that against SC5314. 186 
 187 
DISCUSSION 188 
VT-1598 has previously demonstrated a broad spectrum of activity in vitro against yeasts 189 
such as Candida and Cryptococcus spp., moulds including Aspergillus spp. and endemic fungi 190 
(33), and has shown improved survival and reduced fungal burden in murine models of CNS 191 
coccidioidomycosis (34) and cryptococcosis (35).  Pertinent to the present study, VT-1598 has 192 
also recently shown potent in vitro and in vivo antifungal activity against fluconazole-sensitive 193 
and -resistant Candida spp. isolated from chronic mucocutaneous candidiasis patients (36).  194 
Structurally, while the tetrazole moiety has lower affinity for interaction with the heme iron of 195 
CYP51, other structural modifications have made the drug more fungal-specific.  For example, a 196 
critical H-bond between VT-1598 and the CYP51 enzyme of many fungi likely confers its broad 197 
activity (37).  This greater selectivity may decrease the potential for undesirable adverse effects 198 
and drug interactions that occur with the triazoles through inhibition of human cytochrome P-450 199 
enzymes. 200 
 Our study supports the previous finding that VT-1598 has potent activity against C. 201 
albicans isolates.  Overall, VT-1598 displayed the lowest MIC50 and MIC90 values compared to 202 
fluconazole, voriconazole, posaconazole, itraconazole, and VT-1161 against the clinical isolates 203 
tested.  More importantly, VT-1598 MICs often remained unchanged from its baseline 204 
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measurement against SC5314 and other fluconazole-susceptible clinical isolates even against 205 
isolates containing known resistance mechanisms, indicating that this tetrazole may retain 206 
activity against isolates that are normally less susceptible to other azole antifungals.  This 207 
included multiple fluconazole-resistant isolates with various combinations of CDR1, MDR1 and 208 
ERG11 expression increases and mutations in the ERG11 gene.   209 
 Interestingly, when tested against laboratory strains containing individual azole resistance 210 
mechanisms, VT-1598 MICs changed relatively little.  Traditional azole resistance mechanisms 211 
such as efflux pump overexpression (Cdr1 and Mdr1) and overexpression of the azole target 212 
(Erg11) did not alter VT-1598 MICs within the concentration ranges tested here.  While it is 213 
possible that testing lower concentrations might reveal differences in MIC, the clinical relevance 214 
at such low concentrations is questionable.  Our current finding suggests that these mechanisms 215 
individually are not sufficient to confer resistance to VT-1598.  Previously, the Tyr132 and 216 
Lys143 substitutions in Erg11 were reported to have the strongest individual effects on 217 
fluconazole and voriconazole MICs (20).  The combination substitutions Y132F&K143R and 218 
Y132F&F145L, which have been shown to have some of the strongest increases in fluconazole 219 
and voriconazole MIC, respectively, did not appreciably change the MIC of VT-1598.  Against 220 
VT-1161, both these double substitutions showed less of an effect than the single amino acid 221 
substitution Y132F.  The K143R substitution is thought to alter the H-bond strength of the heme 222 
ring propionates of the C. albicans Erg11 protein, which may possibly interfere with the 223 
coordination of the azole ring nitrogen and the iron of the CYP51 heme group, and the F145L 224 
amino acid substitution is located on the Erg11 proximal surface, allowing possible interactions 225 
with NADPH-cytochrome P450 reductase (20, 38). Based on the crystal structure of the C. 226 
albicans CYP51 enzyme complexed with VT-1161, the Y132F substitution is thought to 227 
11 
 
altogether abolish one of six H-bonds between VT-1161 and the protoporphyrin IX propionates 228 
on Erg11 (38). It is possible that the Y132F substitution is more important to VT-1161 resistance 229 
than either K143R or F145L and that combination mutations might interfere with the primary 230 
Y132F substitution, thus leading to the differences in the observed VT-1161 MICs. 231 
Against a collection of predominantly fluconazole-resistant clinical isolates, VT-1161 232 
showed good activity, though its individual MIC50 and MIC90 were higher compared to VT-233 
1598.  In contrast to VT-1598, the potency of VT-1161 appeared to be more affected by the 234 
presence of CDR1 and MDR1 overexpression and ERG11 mutations.  This was supported by the 235 
significant positive correlation established between CDR1/MDR1 expression and VT-1161 MIC 236 
in C. albicans clinical isolates.  Additionally, susceptibility testing in strains containing 237 
individual mechanisms of azole resistance, wherein the CDR1-overexpressing strains 238 
SCTAC1GAD1A and –B and the MDR1-overexpressing strains SCMRR1GAD1A and -B 239 
demonstrated increased VT-1161 MICs, further supports Mrr1 and Tac1 as mediators of 240 
resistance to VT-1161, at least in part through increased production of the transporters Mdr1 and 241 
Cdr1, respectively. The recent work by Monk et al. also demonstrated that both the Cdr1 and 242 
Mdr1 efflux pumps reduced the effectiveness of VT-1161, and activity against Cdr1- and Mdr1-243 
overexpressing isolates could be restored via the Cdr1- and Mdr1-specific inhibitors RC21v3 and 244 
MCC1189, respectively (39). The Erg11 amino acid substitutions Y132F, Y132F&K143R, and 245 
Y132F&F145L also resulted in shifts in VT-1161 MIC and may contribute to VT-1161 246 
resistance.  However, VT-1161 retained activity against a number of isolates with known azole 247 
resistance mechanisms.  The tested ERG11 mutant strains containing the Y132H, K143R, 248 
F145L, E266D, D278N, S405F, G448E, F449V, G450E, G464S, and D466E single substitutions 249 
and the D278N&G464S, and G450E&I483V double substitutions showed little change in VT-250 
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1161 MICs compared to the susceptible parent strain SC5314. Thus, VT-1161 has potential to be 251 
a future treatment option of azole-resistant C. albicans infections or recurrent infections 252 
previously treated with older members of the azole class. 253 
Within the five clinical isolates that displayed greatly reduced susceptibility to VT-1161, 254 
VT-1598, and the other commercially available triazoles tested, one isolate contained an early 255 
stop codon at Trp131 within the ERG3 gene, which encodes for sterol Δ5,6-desaturase and is 256 
critical for ergosterol biosynthesis in C. albicans.  It has been previously reported that mutations 257 
in ERG3 can result in azole resistance and alternative sterol biosynthesis by avoidance of 258 
accumulation of toxic sterol intermediates through defective desaturase enzyme (26, 27, 40).  259 
The inhibition of the azole target 14α-lanosterol demethylase causes accumulation of the toxic 260 
sterol intermediate, 14α-methylergosta-8,24(28)-dien-3β,6α-diol, which is thought to be the 261 
source of the fungistatic effect seen with azole antifungal class (24, 25, 41).  However, 262 
dysfunctional Erg3 results in alternative sterol usage and an inability to produce this toxic 263 
intermediate.  Therefore, mechanisms that result in a non-functional Erg3 might render an isolate 264 
resistant to the azole antifungal drug class, as is seen in the case of the isolate containing the 265 
premature stop codon in ERG3. 266 
In summary, the in vitro activity of VT-1161 and VT-1598 against azole-resistant C. 267 
albicans clinical isolates and strains with known azole resistance mechanisms suggests that they 268 
may prove useful against resistant C. albicans infections.  Furthermore, given their low and 269 
relatively unchanged MICs against many azole-resistant strains, it is possible that VT-1161 and 270 
VT-1598 may fill some of the gaps in coverage against azole-resistant isolates.  This, in 271 
combination with the potential for favorable safety and drug interaction profiles, makes VT-1161 272 
and VT-1598 attractive options as alternative therapies for azole-resistant C. albicans infections.  273 
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However, the presence of strongly resistant isolates, such as the five clinical isolates with greatly 274 
increased MICs to all azoles tested here, suggests the existence of azole-resistance determinants 275 
that can provide obstacles to the successful utilization of all azoles, including these new 276 
tetrazoles.  Further investigation should be undertaken to identify the mechanism(s) responsible 277 
for resistance to these agents. 278 
 279 
MATERIALS AND METHODS 280 
Isolate and strain growth conditions. Sixty-eight clinical C. albicans isolates were obtained 281 
from the University of Iowa. C. albicans isolates and strains were cultured from -80˚C freezer 282 
stock (40% glycerol in YPD media) onto YPD-agar plates overnight at 30˚C. Colonies from 283 
YPD-agar plates were then either streaked onto Sabouraud Dextrose agar for azole 284 
susceptibility testing or grown in liquid YPD media and incubated overnight at 30˚C for 285 
preparation of genomic DNA. 286 
 287 
Construction of C. albicans strains.  Table 2 lists the constructed strains used in this study. 288 
Ten single ERG11 mutations and four double mutations were selected from previous studies 289 
(20).  Two additional strains expressing the Y132H and D278N ERG11 gene mutations were 290 
created in a previous study utilizing the SAT flipper cassette (42, 43). Briefly, to create the 291 
mutant strain SCERG11R1S1C1, ERG11 gene fragments were generated by primers pairs 292 
CaERG11_1F with CaERG11SOE-3R_Y132H and CaERG11SOE-2F_Y132H with 293 
CaERG11_4R using SC5314 template genomic DNA (Table S3).  Short-overlapping extension 294 
PCR was used to fuse the resulting ERG11 gene fragments using nested primers CaERG11-295 
AF_(ApaI) and CaERG11-BR_(XhoI).  For mutant strain SCERG11R3S3C1, ERG11 gene 296 
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fragments were generated by primers pairs CaERG11_1F with CaERG11SOE-6R using 297 
template genomic DNA from clinical isolate 43 and CaERG11SOE-5F with CaERG11_4R 298 
using SC5314 genomic DNA.  The resulting fragments were again fused into a single fragment 299 
containing either the D278N-containing mutant ERG11 open reading frame (ORF) using nested 300 
primers CaERG11-AF_(ApaI) and CaERG11-BR_(XhoI).  In constructing the plasmids used in 301 
the transformation of both strains, the ERG11 3’ flanking sequence was amplified from SC5314 302 
genomic DNA and primers CaERG11_C-F' and CaERG11_D-R’. The inserts 3’ of the ERG11 303 
ORF were digested with restriction enzymes NotI and SacII, and cloned into the pSFS2-derived 304 
plasmid pBSS2 previously described by Vasicek et al. containing the SAT1 flipper cassette 305 
from Reuβ et al. (42, 44) to create plasmid pERG11CD.  The ERG11 ORF-containing 306 
fragments with either the Y132H or D278N mutations were digested using restriction enzymes 307 
ApaI and XhoI, gel excised, and cloned into the plasmid pERG11CD to generate plasmids 308 
pERG11A1 and pERG11A3.  Plasmids were digested with restriction enzymes ApaI and SacII 309 
and used to transform strain SC5314 by electroporation to generate heterozygous ERG11 310 
mutants.  Recycling of the nourseothricin selection marker through 24 hours of growth in YPD 311 
and repeat transformation of the resultant strains generated the homozygous ERG11 allele 312 
replacements SCERG11R1S1C1 and SCERG11R3S3C1, confirmed via Southern hybridization 313 
and Sanger sequencing.  The artificially-activated Tac1, Mrr1, and Upc2 mutants used in this 314 
study as well as SC∆cdr1TAC1GAD1A and -B, containing the artificially activated TAC1 315 
allele in a cdr1Δbackground, were described in a previous study (45).  Strains 316 
SC∆mdr1MRR1GAD1A and -B were constructed by introducing the artificially activated 317 
MRR1 allele from plasmid pMRR1-GAD1 (32) into the mdr1Δ mutants SCMDR1M4A and -B 318 
(46), respectively. 319 
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 320 
ERG11 amplification and sequencing.  Table S3 lists the primers used for ERG11 321 
amplification and sequence verification.  The ERG11 ORF of each isolate was PCR amplified 322 
from genomic DNA using primers CaERG11_F_Amp and CaERG11_R_Amp.  PCR products 323 
were purified using the QIAquick® PCR Purification Kit (Qiagen) and product was sequenced 324 
on an ABI 3130XL genetic analyzer using sequencing primers. Sequencing was accomplished in 325 
duplicate in independently grown isolates. 326 
 327 
Relative gene expression by real-time PCR.  Expression levels of the genes CDR1, MDR1, and 328 
ERG11 in clinical C. albicans isolates were measured in a previous study, and CDR1, MDR1, 329 
and ERG11 expression of laboratory strains were measured similarly using previously described 330 
methods (19). Briefly, first-strand cDNA was generated from 1 μg of extracted RNA for each 331 
strain using the SuperScript® VILO™ Master Mix (Invitrogen) reaction kit.  Quantitative PCRs 332 
were performed on the StepOnePlus™ Real-Time PCR System (Applied Biosystems) in 333 
technical and biological triplicate for each sample.  SYBR green PCR master mix (Applied 334 
Biosystems) was used for amplification detection of candidate genes against the CaACT1 335 
normalizing gene.  Calculation of the relative quantitation values of CDR1, ERG11, and MDR1 336 
gene expression was accomplished using the StepOne Software v2.3 (Applied Biosystems).  337 
Primers used in the amplification of genes measured via qPCR are listed in Table S3. 338 
 339 
Susceptibility testing.  Minimum inhibitory concentrations (MIC) of VT-1161, VT-1598, 340 
fluconazole, voriconazole, posaconazole, and itraconazole were measured using broth 341 
microdilution methods in accordance with the Clinical Laboratory and Standards Institute (47, 342 
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48).  96-well microtiter plates containing RPMI-1640 media (0.165M MOPS, with L-343 
glutamine, without sodium bicarbonate, pH 7.0) were used to incubate strains across serially-344 
diluted concentrations of the each azole.  Concentrations ranged from 0.015 to 8 μg/mL for VT-345 
1161 and VT-1598, 0.125 to 64 μg/mL for fluconazole, and 0.03 to 16 μg/mL for voriconazole, 346 
posaconazole, and itraconazole.  MICs were visually read at 24 hours post-incubation at 35˚ C 347 
as the minimum concentration required to reduce growth of cells by approximately 50% or 348 
greater compared to drug-free control wells.  MICs were performed in duplicate for clinical 349 
isolates, ERG11 mutant strains and laboratory strains SCTAC1GAD1A and -B, 350 
SCΔcdr1TAC1GAD1A and -B, SCMRR1GAD1A and -B, SCΔmdr1MRR1GAD1A and -B and 351 
SCUPC2GAD1A and -B.  When reporting MICs for strains and isolates, the higher of the MICs 352 
was used in this analysis (Table S1, Table S2), though 98% (592/606) of MIC duplicate 353 
readings were identical or within a single dilution of each other.  The geometric mean MIC 354 
(GM MIC), MIC50, and MIC90 was reported for clinical C. albicans isolates for each triazole 355 
and tetrazole agent used in this study.  The MIC50 and MIC90 values reported for VT-1161, VT-356 
1598, fluconazole, voriconazole, itraconazole, and posaconazole were defined as the minimum 357 
drug concentrations required to inhibit 50% and 90% of the clinical C. albicans isolates tested, 358 
respectively. 359 
 360 
Statistical Analysis. A point-biserial correlation or phi coefficient was used for all continuous 361 
and dichotomous variables, respectively, to identify possible predictors of azole resistance.  For 362 
all statistical tests, a p-value less than 0.05 was considered significant.  Statistical calculations 363 
were performed using IBM® SPSS© analytical software, version 23. 364 
 365 
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Table 1. Geometric mean MICs, MIC50, MIC90, and ranges (µg/mL) for tested compounds against 68 clinical isolates of C. albicans. 536 
Drug GM MIC MIC50 MIC90 Range 
VT-1161 0.15 0.125 1 ≤0.015 - >8 
VT-1598 0.05 0.06 0.25 ≤0.015 - >8 
Fluconazolea 20.2 32 >64 ≤0.125 - >64 
Voriconazoleb 0.32 0.5 2 ≤0.03 - >16 
Itraconazolec 0.31 0.25 1 ≤0.03 - >16 
Posaconazolec,d 0.2 0.5 2 ≤0.03 - >16 
aCLSI clinical breakpoints: resistant ≥8 µg/mL, susceptible dose-dependent 4 µg/mL, susceptible ≤2 µg/mL (48) 
bCLSI clinical breakpoints: resistant ≥1 µg/mL, intermediate 0.25 – 0.5 µg/mL, susceptible ≤0.125 µg/mL (48) 
cn = 66 clinical isolates for itraconazole and posaconazole 
dCLSI epidemiological cutoff value = 0.06 µg/mL (49) 
  537 
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Table 2.  Constructed strains used in this study. 538 
 539 
Strainsa Genotype Source or reference 
SC5314 ERG11-1/ERG11-2 ATCC 
   
Constructed laboratory strainsa   
20E1II1B1 ERG11Y132F::FRT / ERG11Y132F::FRT Flowers et al., 2015 
SCERG11R1S1C1 ERG11Y132H::FRT / ERG11Y132H::FRT Warrilow et al., 2019 
10B1A3A ERG11K143R::FRT / ERG11K143R::FRT Flowers et al., 2015 
2B1A51A ERG11F145L::FRT / ERG11F145L::FRT Flowers et al., 2015 
29NA29A23A ERG1E266D::FRT / ERG11E266D::FRT Flowers et al., 2015 
SCERG11R3S3C1 ERG11D278N::FRT / ERG11D278N::FRT Warrilow et al., 2019 
21C1M1B1 ERG11S405F::FRT / ERG11S405F::FRT Flowers et al., 2015 
20NA11A57A ERG11G448E::FRT / ERG11G448E::FRT Flowers et al., 2015 
7A5A5A ERG11F449V::FRT / ERG11F449V::FRT Flowers et al., 2015 
15A3A108A ERG11G450E::FRT / ERG11G450E::FRT Flowers et al., 2015 
19A1A1C1 ERG11G464S::FRT / ERG11G464S::FRT Flowers et al., 2015 
22B12A58A ERG11D466E::FRT / ERG11D466E::FRT Flowers et al., 2015 
9A14A21A ERG11Y132F,K143R::FRT / ERG11Y132F,K143R::FRT Flowers et al., 2015 
27A5A33A ERG11Y132F,F145L::FRT/ ERG11Y132F,F145L::FRT Flowers et al., 2015 
13A5A57A ERG11D278N,G464S::FRT / ERG11D278N,G464S::FRT Flowers et al., 2015 
8A4A1A ERG11G450E,I483V::FRT / ERG11G450E I483V::FRT Flowers et al., 2015 
SCTAC1GAD1A and -B ADH1/adh1::PADH1-TAC1-GAL4AD-3xHA-caSAT1 Schillig et al., 2013 
SCΔcdr1TAC1GAD1A and -B ADH1/adh1::PADH1-TAC1-GAL4AD-3xHA-caSAT1 Schillig et al., 2013 
 
SCMRR1GAD1B and -B  
cdr1Δ::FRT/cdr1Δ::FRT 
ADH1/adh1::PADH1-MRR1-GAL4AD-3xHA-caSAT1 
 
Schillig et al., 2013 
SCΔmdr1MRR1GAD1A and -B ADH1/adh1::PADH1-MRR1-GAL4AD-3xHA-caSAT1 This study 
 mdr1Δ::FRT/mdr1Δ::FRT  
SCUPC2GAD1A and -B ADH1/adh1::PADH1-UPC2-GAL4AD-3xHA-caSAT1 Schillig et al., 2013 
SCUPC2R14A and -B UPC2G648D::FRT / UPC2G648D::FRT Heilmann et al., 2010 
aAll laboratory strains have SC5314 as background.   
 540 
 541 
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Figure 1. Comparison of the MICs of VT-1161 and VT-1598 against the MICs of (a) fluconazole, (b) 542 
voriconazole, (c) itraconazole, and (d) posaconazole in a collection of C. albicans clinical isolates.  Plotted 543 
points represent the MICs of clinical isolates, with darker points representative of multiple, superimposed 544 
points.  Concentration of points to the lower right of each plot represent favorable activity (low MICs relative to 545 
susceptible isolates) for VT-1161 or VT-1598 versus the comparator azole.  Conversely, points concentrated to 546 
the top left of each plot represent isolates with high MICs of VT-1161 and VT-1598 relative to the comparator 547 
azole.   Solid vertical lines represent the resistant clinical break point for fluconazole and voriconazole, while 548 
dotted vertical lines represent the epidemiological cutoff values for posaconazole. 549 
550 
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Figure 2. MICs of tested azole compounds against strains with individual known azole resistance 551 
mechanisms.  Tested strains include those containing the artificially-activated transcription factors Tac1 and 552 
Mrr1 in strains SCTAC1GAD1A and –B and SCMRR1GAD1A and -B, respectively, as well as ∆cdr1 553 
derivatives of SCTAC1GAD1A (SC∆cdr1TAC1GAD1A and -B), ∆mdr1 derivatives of SCMRR1GAD1A and 554 
-B (SC∆mdr1MRR1GAD1A and -B), and SCUPC2R14A and –B containing the G648D gain-of-function 555 
mutation in UPC2.  The MICs for the strains with artificially activated Tac1, Mrr1, and for the UPC2G648D gain-556 
of-function mutation are displayed as the highest MIC value of both independently created A- and B- strains for 557 
each respective transcription factor.  The relative fold-change in expression compared to the parent strain 558 
SC5314 of (a) CDR1 for SCTAC1GAD1A and B and (b) MDR1 for SCMRR1GAD1A and -B is shown on the 559 
left of the figure. The antifungal MICs of the UPC2G648D homozygous strains SCUPC2R14A and -B is shown in 560 
(c). 561 
  562 
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Figure 3. Relative fold-change compared to SC5314 in MIC of various azole antifungal agents against 563 
strains containing single and double ERG11 mutations.  Open blue circles represent VT-1598 MICs, while 564 
open black circles represent VT-1161.  Open grey diamonds represent fluconazole.  Solid green triangles 565 
represent voriconazole.  Solid orange diamonds represents itraconazole, and solid inverted purple triangles 566 
represent posaconazole.  567 

